Physician profile
Edward Reardon
NPI 1760488449
$402,555.61
in general payments reported to CMS, 2019-2025
31 companies · $42K in 2025
The $42K reported for 2025 was more than what 96% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108K · 2020: $36K · 2021: $53K · 2022: $60K · 2023: $45K · 2024: $59K · 2025: $42K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $112K · Travel and Lodging: $13K · Food and Beverage: $13K · Consulting Fee: $7,360 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $112,477.50 |
| Travel and Lodging | $13,151.59 |
| Food and Beverage | $12,978.41 |
| Consulting Fee | $7,360.00 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $87,151.16 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $86,225.56 | 2020-2025 | Acthar |
| Glaxosmithkline, LLC. | $50,750.08 | 2019-2025 | Benlysta, Nucala |
| Horizon Therapeutics Plc | $44,324.23 | 2019-2023 | Krystexxa |
| Pfizer INC. | $42,439.83 | 2019-2025 | |
| Ucb, INC. | $42,348.51 | 2019-2025 | Bimzelx, Cimzia |
| Mallinckrodt Enterprises LLC | $18,758.79 | 2019 | |
| Novartis Pharmaceuticals Corporation | $9,567.35 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $8,657.69 | 2019 | |
| Janssen Biotech, INC. | $5,532.91 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Amgen INC. | $2,668.53 | 2019-2025 | Krystexxa, Enbrel, Tavneos |
| Lilly USA, LLC | $673.01 | 2019-2023 | Taltz |
| Genzyme Corporation | $628.83 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $388.75 | 2019-2021 | |
| Genentech USA, INC. | $387.94 | 2019-2024 | Actemra |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $353.61 | 2019-2024 | Orencia |
| Astrazeneca Pharmaceuticals LP | $282.01 | 2022-2025 | Saphnelo |
| Celgene Corporation | $270.43 | 2019 | |
| Fresenius Kabi USA, LLC | $213.36 | 2023-2025 | Idacio, Tyenne |
| Ani Pharmaceuticals, INC. | $206.05 | 2022 | |
| Medexus Pharma, INC. | $143.67 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.65 | 2020-2024 | Cyltezo |
| Janssen Scientific Affairs, LLC | $122.88 | 2022 | |
| Merck Sharp & Dohme LLC | $98.37 | 2019-2020 | |
| Organon LLC | $80.13 | 2023-2025 | Renflexis, Hadlima |
| Takeda Pharmaceuticals U.S.A., INC. | $54.38 | 2020-2021 | |
| Depuy Synthes Sales INC. | $31.35 | 2024 | Monovisc, Orthovisc |
| Eyevance Pharmaceuticals LLC | $18.64 | 2021 | |
| Amag Pharmaceuticals, INC. | $17.43 | 2021 | |
| Ferring Pharmaceuticals INC. | $17.39 | 2020 | |
| Sobi, INC | $17.09 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Reardon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.